These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29161692)

  • 21. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
    Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
    Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis.
    Rivara MB; Ravel V; Kalantar-Zadeh K; Streja E; Lau WL; Nissenson AR; Kestenbaum B; de Boer IH; Himmelfarb J; Mehrotra R
    J Am Soc Nephrol; 2015 Jul; 26(7):1671-81. PubMed ID: 25613037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodialysis patients update].
    Okuno S
    Clin Calcium; 2012 Jul; 22(7):1009-17. PubMed ID: 22750933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients.
    Merle E; Roth H; London GM; Jean G; Hannedouche T; Bouchet JL; Drüeke T; Fouque D; Daugas E;
    Kidney Int; 2016 Mar; 89(3):666-74. PubMed ID: 26880460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective.
    Jadoul M; Martin P
    Blood Purif; 2017; 43(1-3):206-209. PubMed ID: 28114144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new player in chronic kidney disease mineral and bone disorder: tenascin-C.
    Ozkan G; Ulusoy S; Guvercin B; Menteşe A; Karahan SC; Yavuz A
    Int J Artif Organs; 2015 Sep; 38(9):481-7. PubMed ID: 26449567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and outcomes associated with hypocalcaemia and hypercalcaemia among pre-dialysis chronic kidney disease patients with mineral and bone disorder.
    Yong MHA; Seng JJB; Tan YLC; Wong J; How P
    Singapore Med J; 2024 Aug; 65(8):421-429. PubMed ID: 36453429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target phosphate and calcium levels in patients undergoing hemodialysis: a post-hoc analysis of the LANDMARK study.
    Yoshida K; Mizukami T; Fukagawa M; Akizawa T; Morohoshi H; Sambe T; Ito H; Ogata H; Uchida N;
    Clin Exp Nephrol; 2023 Feb; 27(2):179-187. PubMed ID: 36303046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5.
    Alderson HV; Ritchie JP; Middleton R; Larsson A; Larsson TE; Kalra PA
    Nephrology (Carlton); 2016 Jul; 21(7):566-73. PubMed ID: 27334353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder.
    Seng JJB; Tan YLC; Lim RW; Ng HTS; Lee PH; Wong J
    Int Urol Nephrol; 2018 Oct; 50(10):1871-1877. PubMed ID: 29882003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac Troponin T and Hydration Status as Prognostic Markers in Hemodialysis Patients.
    Hoppe K; Schwermer K; Klysz P; Radziszewska D; Sawatiuk P; Baum E; Kaczmarek J; Roszak M; Kaluzna M; Lindholm B; Pawlaczyk K; Oko A
    Blood Purif; 2015; 40(2):139-45. PubMed ID: 26184399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The demise of calcium-based phosphate binders-is this appropriate for children?
    Rees L; Shroff R
    Pediatr Nephrol; 2015 Dec; 30(12):2061-71. PubMed ID: 25543193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac troponin T elevation at dialysis initiation is associated with all-cause and cardiovascular mortality on dialysis in patients without diabetic nephropathy.
    Hayashi T; Kimura T; Yasuda K; Sasaki K; Obi Y; Rakugi H; Isaka Y
    Clin Exp Nephrol; 2017 Apr; 21(2):333-341. PubMed ID: 27178276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
    Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.
    Žamboch K; Krejčí K; Škarda J; Tichý M; Überall I; Skýpalová P; Langová K; Stejskal D; Švesták M; Zahálková J; Ščudla V; Zadražil J
    Int Urol Nephrol; 2015 Jul; 47(7):1195-201. PubMed ID: 25931273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional impairment attenuates the association between high serum phosphate and mortality in dialysis patients: a nationwide cohort study.
    Wakasugi M; Kazama JJ; Wada A; Hamano T; Masakane I; Narita I
    Nephrol Dial Transplant; 2019 Jul; 34(7):1207-1216. PubMed ID: 30124993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.